These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 19391290)

  • 1. Bisphosphonates: bone, muscle and joint pain.
    Prescrire Int; 2009 Feb; 18(99):23. PubMed ID: 19391290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
    Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
    J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of bisphosphonates in the treatment of osteoporosis.
    Recker RR; Lewiecki EM; Miller PD; Reiffel J
    Am J Med; 2009 Feb; 122(2 Suppl):S22-32. PubMed ID: 19187809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient- and physician-oriented web sites and drug surveillance: bisphosphonates and severe bone, joint, and muscle pain.
    Demonaco HJ
    Arch Intern Med; 2009 Jun; 169(12):1164-6. PubMed ID: 19546419
    [No Abstract]   [Full Text] [Related]  

  • 5. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.
    Caplan L; Pittman CB; Zeringue AL; Scherrer JF; Wehmeier KR; Cunningham FE; Eisen SA; McDonald JR
    Mayo Clin Proc; 2010 Apr; 85(4):341-8. PubMed ID: 20231335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis treatments and adverse events.
    Solomon DH; Rekedal L; Cadarette SM
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current controversies in bisphosphonate therapy.
    Kamath AF
    Orthopedics; 2009 Jul; 32(7):473. PubMed ID: 19634857
    [No Abstract]   [Full Text] [Related]  

  • 8. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
    Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
    Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw due to bisphosphonates.
    Prescrire Int; 2008 Oct; 17(97):202-3. PubMed ID: 19536938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronic acid: synovitis, myalgia and arthralgia.
    Prescrire Int; 2007 Apr; 16(88):72. PubMed ID: 17465037
    [No Abstract]   [Full Text] [Related]  

  • 11. New developments surrounding the safety of bisphosphonates.
    Arum SM
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec; 15(6):508-13. PubMed ID: 18971679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bisphosphonates-associated osteonecrosis in rheumatoid arthritis.
    Junquera L; Gallego L; Pelaz A; Olay S
    Med Oral Patol Oral Cir Bucal; 2009 Jun; 14(6):E292-4. PubMed ID: 19300372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral uveitis secondary to bisphosphonate therapy.
    Tan YL; Sims J; Chee SP
    Ophthalmologica; 2009; 223(3):215-6. PubMed ID: 19221448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
    Fehm T; Felsenberg D; Krimmel M; Solomayer E; Wallwiener D; Hadjii P
    Breast; 2009 Aug; 18(4):213-7. PubMed ID: 19651512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients.
    Thumbigere-Math V; Sabino MC; Gopalakrishnan R; Huckabay S; Dudek AZ; Basu S; Hughes PJ; Michalowicz BS; Leach JW; Swenson KK; Swift JQ; Adkinson C; Basi DL
    J Oral Maxillofac Surg; 2009 Sep; 67(9):1904-13. PubMed ID: 19686928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
    Wysowski DK; Chang JT
    Arch Intern Med; 2005 Feb; 165(3):346-7. PubMed ID: 15710802
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonate therapy. No fear of erosions].
    MMW Fortschr Med; 2001 Apr; 143(16):60. PubMed ID: 11372073
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical features of pregnancy and lactation-associated osteoporosis: analysis of 4 cases].
    He XD; Xia WB; Xing XP; Li M; Jiang Y; Wang O; Xu LL; Xu JP
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(14):983-5. PubMed ID: 19671313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.